Search Results
Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Joachim N Nilsson in
Google Scholar
PubMed
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Jonathan Siikanen in
Google Scholar
PubMed
Search for other papers by Vincenzo Condello in
Google Scholar
PubMed
Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Kenbugul Jatta in
Google Scholar
PubMed
Search for other papers by Ravi Saini in
Google Scholar
PubMed
Stockholms Sjukhem Foundation's Research and Development Department, Stockholm, Sweden
Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Search for other papers by Christel Hedman in
Google Scholar
PubMed
Department of Breast, Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Catharina Ihre Lundgren in
Google Scholar
PubMed
Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by C Christofer Juhlin in
Google Scholar
PubMed
adequate uptake and trapping of iodine in the target tissue, which is conceptualised as iodine avidity. For most patients with low-risk disease, post-surgical treatment includes thyroid remnant ablation – a highly iodine avid target. However, in the
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Paul Stewardson in
Google Scholar
PubMed
Search for other papers by John B McIntyre in
Google Scholar
PubMed
Search for other papers by Adrian Box in
Google Scholar
PubMed
Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Search for other papers by Martin Hyrcza in
Google Scholar
PubMed
Search for other papers by Konstantin Koro in
Google Scholar
PubMed
Search for other papers by Dean Ruether in
Google Scholar
PubMed
Search for other papers by Jiahui Wu in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
were found in 12.6% of patients and RET gene fusions in 14.3% ( 13 ). The prevalence of fusions increases for metastatic/advanced patients’ WT of other aberrations. In radioactive iodine (RAI)-resistant metastatic thyroid cancers without BRAF
Search for other papers by Abdul Rehman Syed in
Google Scholar
PubMed
Search for other papers by Aakash Gorana in
Google Scholar
PubMed
Search for other papers by Erik Nohr in
Google Scholar
PubMed
Search for other papers by Xiaoli-Kat Yuan in
Google Scholar
PubMed
Search for other papers by Parthiv Amin MASc in
Google Scholar
PubMed
Search for other papers by Sana Ghaznavi in
Google Scholar
PubMed
Search for other papers by Debbie Lamb in
Google Scholar
PubMed
Search for other papers by John McIntyre in
Google Scholar
PubMed
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
://doi.org/10.1056/NEJMoa1209288 ) 7 Rothenberg SM McFadden DG Palmer EL Daniels GH & Wirth LJ . Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib . Clinical Cancer Research 2015 21 1028
Search for other papers by Hélène Théodon in
Google Scholar
PubMed
Search for other papers by Erell Guillerm in
Google Scholar
PubMed
Search for other papers by Johanna Wassermann in
Google Scholar
PubMed
Search for other papers by Gabrielle Deniziaut in
Google Scholar
PubMed
Search for other papers by Loïc Jaffrelot in
Google Scholar
PubMed
Search for other papers by Jérome Denis in
Google Scholar
PubMed
Search for other papers by Nathalie Chereau in
Google Scholar
PubMed
Search for other papers by Claude Bigorgne in
Google Scholar
PubMed
Search for other papers by Wiame Potonnier in
Google Scholar
PubMed
Search for other papers by Florence Coulet in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Camille Buffet in
Google Scholar
PubMed
, 2 ). Today, tumor molecular genotyping plays a key role in the management of radioactive iodine refractory (RAIR) thyroid cancers, as patients with cancers harboring a specific mutation or fusion can be offered highly specific targeted therapies ( 3
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Alexandra Stephenson in
Google Scholar
PubMed
Search for other papers by Shideh Mirhadi in
Google Scholar
PubMed
Search for other papers by Konrad Patyra in
Google Scholar
PubMed
Search for other papers by Michael F Moran in
Google Scholar
PubMed
Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Department of Pediatrics, Turku University Hospital, Turku, Finland
Search for other papers by Jukka Kero in
Google Scholar
PubMed
Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Department of Medicine, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
, University of Turku. Animals were provided access to water and pelleted chow ad libitum (SDS RM-3 (P); Special Diet Service). The chow contained 0.4 mg/kg iodine, which has been previously shown to be sufficient for thyroid function ( 21 ). For hormone
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Search for other papers by Massimiliano Succi in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
R Siena S Bastholt L de la Fouchardiere C Pacini F Paschke R Shong YK , et al. DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double
Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul, South Korea
Search for other papers by Hyun-Jin Lee in
Google Scholar
PubMed
Search for other papers by Young-Sool Hah in
Google Scholar
PubMed
Search for other papers by So Young Cheon in
Google Scholar
PubMed
Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University Hospital, Jinju, South Korea
Institute of Health Sciences, Gyeongsang National University, Jinju, South Korea
Search for other papers by Seong Jun Won in
Google Scholar
PubMed
Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University Hospital, Jinju, South Korea
Institute of Health Sciences, Gyeongsang National University, Jinju, South Korea
Search for other papers by Chae Dong Yim in
Google Scholar
PubMed
Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University Hospital, Jinju, South Korea
Institute of Health Sciences, Gyeongsang National University, Jinju, South Korea
Search for other papers by Somi Ryu in
Google Scholar
PubMed
Search for other papers by Seung-Jun Lee in
Google Scholar
PubMed
Department of Pediatrics, Gyeongsang National University College of Medicine, Jinju, South Korea
Search for other papers by Ji Hyun Seo in
Google Scholar
PubMed
Biomedical Research Institute, Gyeongsang National University Hospital, Jinju, South Korea
Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University Hospital, Jinju, South Korea
Institute of Health Sciences, Gyeongsang National University, Jinju, South Korea
Search for other papers by Jung Je Park in
Google Scholar
PubMed
-year survival rate is approximately 93% ( 2 ). Most cases are treated effectively by surgical resection followed by radioactive iodine therapy; however, in some cases, the disease shows an aggressive nature and does not respond to conventional